Department of Otorhinolaryngology, Head and Neck Surgery, Berlin Institute of Health, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany; Division of Molecular Diagnostics, Department of Laboratory Medicine, Zhejiang Cancer Hospital, Hangzhou, PR China; Key Laboratory of Laboratory Medicine, Ministry of Education, Zhejiang Provincial Key Laboratory of Medical Genetics, Wenzhou Medical University, Wenzhou, PR China.
Key Laboratory of Receptors-Mediated Gene Regulation and Drug Discovery, School of Basic Medical Sciences, Henan University, Kaifeng, PR China.
Semin Cancer Biol. 2018 Dec;53:248-257. doi: 10.1016/j.semcancer.2018.06.001. Epub 2018 Jun 20.
One of the greatest challenges in systemic treatment of head and neck squamous cell carcinoma (HNSCC) is a small tumor cell population, namely, cancer stem-like cells (CSC). CSC can regenerate and maintain a heterogenic tumor by their self-renewal capacity. Their potential ability to be more resistant to and survival after chemo- and radiation therapy was also identified. Further studies have shown that reactive oxygen species (ROS) contribute to this CSC-associated resistance. In this review, we focus on the current knowledge of HNSCC-CSC, with regard to ROS as a possible and novel therapeutic approach in targeting CSC.
头颈部鳞状细胞癌（HNSCC）系统治疗的最大挑战之一是一小部分肿瘤细胞，即癌症干细胞样细胞（CSC）。CSC 具有自我更新能力，可以再生和维持异质性肿瘤。还发现它们对化疗和放疗的耐药性和生存能力更强。进一步的研究表明，活性氧（ROS）有助于这种与 CSC 相关的耐药性。在这篇综述中，我们专注于 HNSCC-CSC 的最新知识，探讨 ROS 作为一种针对 CSC 的可能的新治疗方法。
